Lisa A. Carey, MD, on Locally Recurrent or Metastatic Breast Cancer: Results of a CALGB/NCCTG Trial
2017 San Antonio Breast Cancer SymposiumLisa A. Carey, MD, of the University of North Carolina, discusses the long-term follow-up of CALGB 40502/NCCTG N063H, a phase III study of weekly paclitaxel compared with weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (Abstract GS3-06).
Related Videos
Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial
Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve dis...
Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial
Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or doceta...
Keynote Lecture: Silvia C. Formenti, MD, on Converting Tumors Into in Situ Vaccines With Radiation Therapy
Silvia C. Formenti, MD, of Weill Cornell Medicine, discusses the high therapeutic potential of combining radiotherapy with immunotherapy and findings that show radiation dose and f...
Eun-Sil Shelley Hwang, MD, on DCIS: Results of the CALGB 40903 Trial
Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstrac...
Vered Stearns, MD, and Prudence A. Francis, MD, on ER+ Breast Cancer: Controversies in Adjuvant Treatment
Vered Stearns, MD, of Johns Hopkins University, and Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre, discuss two key topics in adjuvant treatment: en...
